Navigation Links
Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes
Date:5/20/2013

SAN DIEGO, May 20, 2013 /PRNewswire/ -- Enrollment of patients with Type 2 diabetes is underway in Elcelyx Therapeutics' Phase 2b dose-finding clinical trial of product candidate NewMet™, a delayed-release formulation of generic metformin, the foundational treatment for Type 2 diabetes. Elcelyx expects to complete enrollment of 240 patients in the multicenter U.S. program in June. Results of the trial's primary endpoint of change in fasting plasma glucose are expected in late summer, and the read-out for long-term glucose lowering and weight benefits is due in the fourth quarter of 2013.

Elcelyx has not changed the way metformin works but instead, has discovered how and where metformin works and has leveraged that understanding to develop an improved product. Elcelyx believes metformin's primary site of action is the lower bowel rather than the circulation. By targeting the lower bowel, NewMet dramatically reduces the amount of active ingredient in the bloodstream while still maintaining metformin's potent glucose lowering benefit. Phase 2a trial results indicate that a significantly lower once-daily dose of NewMet that maintains efficacy may meaningfully reduce metformin's gastrointestinal side effects and eliminate the need for titration to initiate treatment.

"Elcelyx's approach of reducing bioavailability of metformin is quite ingenious and turns on its head the incorrect belief that greater exposure to metformin is needed for superior therapeutic benefit," said Ralph A. DeFronzo, M.D., Professor of Medicine and Chief of the Diabetes Division at the University of Texas Health Science Center and the Audie L. Murphy Memorial Veterans Administration Hospital in San Antonio, Texas. "Results from previous NewMet trials indicate that by targeting the hormone-producing enteroendocrine cells in the lower gut, NewMet may have better tolerability with the preserved efficacy of metformin at a lower dose. This would make NewMet ideal for the millions of Type 2 diabetes patients who have difficulty tolerating metformin or are unable to take the medication due to contraindications. I am eager to see the results of the additional planned clinical studies of NewMet to further understand this attractive profile."

Dr. DeFronzo is a world-renowned clinician, teacher and investigator who led the trials that supported the U.S. Food and Drug Administration approval of metformin in 1994. He and fellow investigators will be presenting the Elcelyx-sponsored NewMet Phase 2a trial results at the 2013 American Diabetes Association Scientific Sessions in June.

This randomized, double-blind, dose-finding Phase 2b trial is evaluating NewMet once-daily doses of 1,000, 800 and 600 milligrams compared to placebo. There are also two comparator arms with generic extended-release metformin dosed once-daily at 1,000 and 2,000 milligrams. The primary endpoint of the study is fasting plasma glucose at 4 weeks of treatment. Secondary endpoints through 12 weeks include changes in fasting plasma glucose, hemoglobin A1c, weight and measures of safety and tolerability. 

"Our research has been eye opening for physicians and endocrinologists who appreciate the clinical benefits of metformin such as glucose control and weight loss but are frustrated by its gastrointestinal side effects, need for titration and exclusion of patients with moderate and severe impaired kidney function. Type 2 diabetes patients who have difficulty tolerating generic metformin either come off of it completely or drop down to a less than maximally effective dose," explained Alain Baron , M.D., President and Chief Executive Officer of Elcelyx Therapeutics. "The goal of this study is to demonstrate that NewMet has long-term glucose lowering benefits with a tolerability and safety profile that is superior to currently marketed metformin, the #1 diabetes product in the world. This would allow many more patients with Type 2 diabetes to enjoy the full benefit of metformin's active ingredient."

In Phase 2a studies in patients with Type 2 diabetes, NewMet reduced fasting plasma glucose to a similar extent as generic metformin but had improved tolerability.  Pharmacokinetic/pharmacodynamic studies have shown that glucose lowering and augmented release of the gut hormones peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) were similar to generic metformin despite NewMet's dramatically lower plasma exposure.

By targeting the lower gut and reducing systemic absorption, NewMet may be appropriate for the large population of renally impaired patients with Type 2 diabetes that are contraindicated for metformin use due to the risk of lactic acidosis, a life-threatening result of metformin build-up in the blood. There are few safe and sufficiently effective oral agents to treat Type 2 diabetes patients with renal impairment. Elcelyx plans to initiate a pharmacokinetics/pharmacodynamics study of NewMet in Type 2 diabetes patients with mild, moderate and severe renal impairment. The study is expected to begin this summer.

NewMet is also an ideal candidate for fixed-dosed combinations with other oral antidiabetic agents, such as DPP4is and SGLT2is, because it can deliver a maximally effective dose of metformin in a single once-daily tablet and does not require titration.

About Elcelyx Therapeutics
Elcelyx Therapeutics develops pharmaceutical and consumer healthcare products based on its proprietary Gut Sensory Modulation (GSM) platform. Pharmaceutical product candidate NewMet™ is being developed for use by Type 2 diabetes patients who have difficulty tolerating generic metformin or are contraindicated for its use. In the consumer health area, Elcelyx is developing Lovidia™ as a dietary supplement for weight management. These product candidates are backed by rigorous science and clinical data and present near-term, blockbuster commercial opportunities.  Elcelyx is based in San Diego, CA. For more information, visit www.Elcelyx.com.


'/>"/>
SOURCE Elcelyx Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Elcelyx Therapeutics Names Mark Wiggins Senior Vice President of Business Development, Ginger Graham to Board of Directors
2. Elcelyx Therapeutics Completes $20 Million Series C Financing to Advance NewMet and Lovidia
3. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
4. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
5. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
8. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
9. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
10. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
11. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , Mar. 23, 2017 Research and Markets ... Market: Analysis By Procedure, Replacement Procedure By Technique, Repair Procedure By ... ... Valve Devices Market is forecasted to grow at a CAGR of ... devices is driven by rising aging population, growth in population with ...
(Date:3/23/2017)... March 23, 2017 ... created through extensive primary research (inputs from industry ... aims to present the analysis of global heart ... (Replacement and Repair); Replacement Procedure By Technique (Mechanical, ... Technique (Surgical Devices, Balloon Valvuloplasty, Transcatheter Mitral Valve ...
(Date:3/23/2017)... 23, 2017 As a result of ... the prevalence of allergic diseases, cutting edge developments ... revolutionising the ways in which pharmaceutical and biotech ... promises to be both a high quality meeting ... interest groups, immunologists, research scholars and doctors. The ...
Breaking Medicine Technology:
(Date:3/25/2017)... ... March 25, 2017 , ... Getting earned media coverage meaningful for Garden ... , All through the year, Garden Media aims to provide material helpful to clients’ ... and pitching client’s key messages to gain coveted media placements, Garden Media ...
(Date:3/24/2017)... ... March 24, 2017 , ... Infectious disease affects billions ... the United States, it’s a threat that is constantly changing and evolving. Mediaplanet's ... and offers strategies for the healthcare community to help decrease the number of ...
(Date:3/24/2017)... , ... March 24, 2017 , ... The iaedp Foundation, ... other medical professionals caring for those suffering from the full spectrum of disordered eating, ... as eating disorders professionals from nearly all 50 states and several countries converged on ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... Assili, announce that they are now offering treatments for sleep apnea and TMJ ... dental offices. Sleep apnea , specifically the obstructive type, is increasingly being ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... year of enhancements, upgrading their training and leads programs. , In February, 2017, ... for elite sales agents, Performance Partners is designed to teach how to maximize ...
Breaking Medicine News(10 mins):